Efficacy of Apixaban in Treating Portal Vein Thrombosis Occurring More Than One Year After LSD
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorNorthern Jiangsu People's Hospital
About this trial
The purpose of this study is to determine whether Apixaban is effective and safe in the treatment of portal vein thrombosis Occurring more than one year after laparoscopic splenectomy and azygoportal disconnection.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
A clinical, radiological, or histologic diagnosis of cirrhosis of any etiology.
Portal hypertension bleeding .
Splenomegaly with secondary hypersplenism.
No evidence of portal vein thrombosis by ultrasound evaluation and angio-CT prior to surgery.
Disqualifiers
Hepatocellular carcinoma or any other malignancy.
Hypercoagulable state other than the liver disease related.
DRUGS- oral contraceptives, anticoagulation or anti-platelet drugs.
Child - Pugh C
Trial design
Design model
Single group
Treatments tested in this trial
Apixaban 2.5 MG
DrugIf portal vein thrombosis occurs more than one year after laparoscopic splenectomy and azygoportal disconnection, the patient will orally received 2.5 mg of apixaban (CTTQ, Nanjing, China) twice daily. Then, Doppler ultrasound screening or contrast-enhanced CT scans will be used to evaluate the changes in portal vein thrombosis after apixaban treatment. If it is effective, patients will take apixaban all the time.
Treatment groups
20 Participants
are divided into 1 treatment groupGroup A: Apixaban groupExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Proportion of complete recanalization of portal vein thrombosis
Proportion of complete recanalization of portal vein thrombosis
Time frame
Follow-up of 6 months or greaterSecondary outcomes
1
Proportion of partial recanalization of portal vein thrombosis
Proportion of partial recanalization of portal vein thrombosis
Time frame
Follow-up of 6 months or greaterSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov